These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29541941)

  • 21. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
    Zhang CH; Guo ZM; Zheng HY; Lu JH; Wang YF; Yan XG; Zhao Y; DU XW; Zhang X; Fang L; Ling WH; Qi SY; Yu XB; Zhong NS
    Chin Med J (Engl); 2004 Nov; 117(11):1625-9. PubMed ID: 15569476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques.
    Kobinger GP; Figueredo JM; Rowe T; Zhi Y; Gao G; Sanmiguel JC; Bell P; Wivel NA; Zitzow LA; Flieder DB; Hogan RJ; Wilson JM
    Vaccine; 2007 Jul; 25(28):5220-31. PubMed ID: 17559989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
    Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
    J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.
    He Y; Zhou Y; Wu H; Luo B; Chen J; Li W; Jiang S
    J Immunol; 2004 Sep; 173(6):4050-7. PubMed ID: 15356154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of SARS inactivated vaccine in BALB/c mice.
    Xiong S; Wang YF; Zhang MY; Liu XJ; Zhang CH; Liu SS; Qian CW; Li JX; Lu JH; Wan ZY; Zheng HY; Yan XG; Meng MJ; Fan JL
    Immunol Lett; 2004 Sep; 95(2):139-43. PubMed ID: 15388253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS.
    Yip MS; Leung HL; Li PH; Cheung CY; Dutry I; Li D; Daëron M; Bruzzone R; Peiris JS; Jaume M
    Hong Kong Med J; 2016 Jun; 22(3 Suppl 4):25-31. PubMed ID: 27390007
    [No Abstract]   [Full Text] [Related]  

  • 27. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
    Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters.
    Lamirande EW; DeDiego ML; Roberts A; Jackson JP; Alvarez E; Sheahan T; Shieh WJ; Zaki SR; Baric R; Enjuanes L; Subbarao K
    J Virol; 2008 Aug; 82(15):7721-4. PubMed ID: 18463152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
    Agrawal AS; Tao X; Algaissi A; Garron T; Narayanan K; Peng BH; Couch RB; Tseng CT
    Hum Vaccin Immunother; 2016 Sep; 12(9):2351-6. PubMed ID: 27269431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies of SARS virus vaccines.
    Zheng BJ; Du LY; Zhao GY; Lin YP; Sui HY; Chan C; Ma S; Guan Y; Yuen KY
    Hong Kong Med J; 2008 Aug; 14 Suppl 4():39-43. PubMed ID: 18708674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
    Suresh MR; Bhatnagar PK; Das D
    J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
    Bolles M; Deming D; Long K; Agnihothram S; Whitmore A; Ferris M; Funkhouser W; Gralinski L; Totura A; Heise M; Baric RS
    J Virol; 2011 Dec; 85(23):12201-15. PubMed ID: 21937658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?
    Beretta A; Cranage M; Zipeto D
    Front Immunol; 2020; 11():567710. PubMed ID: 33178193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
    Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
    Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children.
    Zhang Y; Wang L; Liao Y; Liu L; Ma K; Yang E; Wang J; Che Y; Jiang L; Pu J; Guo L; Feng M; Liang Y; Cui W; Yang H; Li Q
    Vaccine; 2015 Nov; 33(46):6290-7. PubMed ID: 26419198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronavirus vaccine-associated lung immunopathology-what is the significance?
    Bottazzi ME; Strych U; Hotez PJ; Corry DB
    Microbes Infect; 2020 Oct; 22(9):403-404. PubMed ID: 32599077
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.